Drug absorption from gastrointestinal tract is mainly influenced by solubility and permeability. As a technique of the improvement of solubility, micronization, amorphousization and the addition of surfactant such as Tween 80 and Captisol ® are well known. As for the improvement of permeability, the use of absorption enhancers is well known, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] but the practical use of them has been very limited 12, 13) because of the potential local toxicity to gastrointestinal mucosa. 2, 4) In order to develop the safe formulation that can improve the absorption of drugs categorized into BCS Class IV such as rebamipide, [14] [15] [16] [17] [18] [19] [20] we have compared the suppository that contains sodium laurate (C12) as an absorption enhancer and taurine (Tau) as a cytoprotective adjuvant with the commercial suppository that contains sodium caprate (C10) as an absorption enhancer. [21] [22] [23] We have found that C12, a mediumchain fatty acid salt, is a promising absorption enhancer and better than C10 in terms of the absorption improving ability, 24) and that Tau has the most effective cytoprotective activity among amino acids examined. 25) Cytoprotective action by Tau has been evidenced by both biochemical [25] [26] [27] and histopathological 25) approaches and it has been partially related with the suppression of intracellular Ca 2ϩ level elevated by C12 and the inhibition of histamine release induced by C12. L-Glutamine (L-Gln) also has the cytoprotective action, which is partially attributed to the induction of heat-shock protein 70 (HSP70), 27) a factor protecting cells from injuries caused by several kinds of stresses. 28, 29) Furthermore, basic studies for suppository were performed in rats by administering the fatty or water-soluble base preparation containing rebamipide, C12 and Tau or L-Gln into rats. The combinatorial use of them, especially for the fatty base (FB) suppository, has been evidenced to be promising in terms of both improvement of bioavailability and safety to rat rectal mucosa.
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In the present study, we have, therefore, performed the scaling-up study of animal and formulation size using FB suppositories of rebamipide and have compared our new preparations with the commercial suppository containing C10 (15 or 25 mg) in terms of the drug dissolution, absorption improvement and safety to the rectal mucosa of rabbits.
MATERIALS AND METHODS
Materials C12, C10 and Tau were purchased from Tokyo Chemical Industry Co. (Tokyo, Japan). Hydroxypropyl methylcellulose (HPMC) TC-5E (HPMC 2910) was purchased from Shin-etsu Kagaku Co. (Tokyo). Witepsol ® H-15 was obtained from Mitsuba Boueki Co. Ltd. (Tokyo). Rebamipide and OPC-12853, an internal standard, were obtained from Otsuka Pharmaceutical Co. Ltd. (Tokushima, Japan). All other reagents were analytical grade commercial products.
Animals Male Japan-White rabbits (Kitayama Labes, Ina, Japan), maintained at 23°C and 60% humidity, were allowed free access to standard laboratory chow (Oriental Yeast Co. Ltd., Tokyo) and water prior to the experiments. Rabbits weighing about 2.8 kg were assigned randomly to 31) the mold was left at room temperature until the mixture was solidified. The obtained suppositories were stored at 10°C and used within 1 week.
Optimization of Suppository Preparation
Dissolution Study The dissolution test was carried out according to the rotating basket method using the dissolution test system DT-610 (JASCO Co., Tokyo). JP 2nd fluid as a test medium was used at 900 ml in a vessel. The basket rotation speed was 50 rpm. The concentration of rebamipide was determined spectrophotometrically (UV detector V-530 UV/VIS spectrophotometer, JASCO Co.) by the difference in absorbance at the wavelengths between 230 nm and 370 nm.
Absorption Study The absorption of rebamipide was estimated by performing the rectal administration study. A suppository containing 5 mg rebamipide was inserted into the rectum and placed about 5 cm from the anus (Fig. 1) , which was clipped as soon as possible. Blood samples were periodically taken from the auricular vein. Area under the serum concentration-time curve (AUC) was calculated from 0 to 6 h according to the trapezoidal rule.
Intravenous Administration Study Intravenous administration study was performed to determine the absolute bioavailability (BA) after rectal administration of rebamipide. Rebamipide solution (1.72 mg/ml) was prepared with 1% (w/v) HPMC and a proper amount of 1 N NaOH in saline and was administered from an auricular vein at a volume of 0.67 ml/kg. Serum concentration-time profiles were analyzed by 2-compartment model with MULTI program 32) and AUC was calculated from 0 to infinite by using the obtained parameters.
Histopathological Evaluation of Local Toxicity After washing the lumen using saline, the rectal lumen was carved out. The segment was then removed and immersed in 10% neutral formalin buffer. Four vertical sections, of which the length is 2.5 cm, were prepared ( Fig. 1 ) and stained with hematoxylin-eosin, and were examined by light microscopy. In each section, various measures of histopathological abnormality were quantified on an arbitrary scale of 0-4, with 0 indicating no effect and 4 indicating a severe effect based on the criteria shown in Table 1 , and then the median and mean of scores of 4 sections were calculated. Finally, overall classification of tissue irritation was performed following the criteria shown in Table 2 . This evaluation was based on the method by Tateda et al. 33) and was carried out by an experienced veterinary histopathologist in a blinded fashion.
Determination of Rebamipide in Serum Serum was separated from blood using Separapid tube S (Sekisui Medical, Osaka, Japan). HPLC-grade acetonitrile (0.2 ml) including OPC-12853 was added to 0.2 ml of serum. After vortex mixing and left for 30 min, the distilled water (0.2 ml) was added to the mixture. Following centrifugation at 14000 rpm Histopathological examination was performed 6 h after dosing suppository by an experienced veterinary histopathologist according to the blinded fashion. If the multiple findings were recognized, higher score was adapted in this evaluation.
for 5 min (HIMAC centrifuge, HITACHI, Tokyo), the supernatant was filtrated with a microfilter (pore size 0.5 mm, Millipore, Tokyo) and introduced into HPLC system, which consisted of a model of CCPM HPLC pump (Tosoh, Tokyo) and a fluorescence detector (SF-8010; Tosoh) set at Ex. 330 nm and Em. 370 nm. Pre-column and analytical column were BSA-ODS (35ϫ4.6 mm i.d., Tosoh) and ODS-80 TM (150ϫ6.0 mm i.d., Tosoh), respectively. The mobile phase, acetonitrile : 5 mM Na 2 SO 4 (3 : 5, v/v) including 1% acetic acid and 0.3% tetrahydrofuran, was delivered at 1.5 ml/min. The retention times of rebamipide and OPC-12853 in this system were 9.5 and 11.5 min, respectively. The range of standard curve was from 20 to 2000 ng/ml and the coefficient of variation for the standard curve ranged from 0.1 to 20.0%. The correlation coefficient was over 0.980.
Statistical Analysis Results are expressed as the meanϮS.E. of three experiments or more. Analysis of variance (ANOVA) was used to test the statistical significance of differences among groups. Statistical significance in the differences of the means was determined by Duncan's method.
RESULTS AND DISCUSSION
The compositions of FB suppository are exhibited in Table  3 . Witepsol ® H-15, which is often used in commercial formula, was used as a main fatty base, because FB suppositories using Witepsol ® H-15 were significantly better than water-soluble base suppositories using polyethylene glycol in terms of the improvement of bioavailability of rebamipide in our basic study using rats.
30) The amount ratio of C12 to Tau used in the rat study was also employed in the rabbit study (suppository h), because it showed the good absorption-improving effect for rebamipide and the cytoprotective effect of Tau. 30) As the total weight of suppositories used in rabbit was about 5 times larger than that in rat, compositions of suppositories were also changed. Therefore, various doses of Tau were examined in terms of cytoprotective action and absorption enhancement. To reveal that our suppositories are better than commercial products, we compared the suppositories containing the same amounts of C10 (15, 25 mg) as those in ampicillin suppository commercially available in Japan with our preparations in terms of absorption-improving effect and local irritation.
Dissolution study was performed for seven typical formulations (Fig. 2) . Dissolution rates calculated as a slope of an initial straight portion of dissolution profile (Fig. 2) are summarized in Table 4 , as zero order kinetics is most suitable for describing the dissolution of rebamipide from suppositories. Although the dissolution rate of rebamipide from FB suppository was very low, it was remarkably improved by the addition of C10 or C12 into FB suppository. This improvement of dissolution might be due to the surface activity that C10 or C12 has, leading to the enhancement of the wettability of rebamipide to JP 2nd fluid. The results also showed that less amount of C12 improved the dissolution rate of rebamipide much more than C10. The addition of Tau to the suppository containing 20-mg C12 only slightly decreased the dissolution of rebamipide, although the dissolution rate was remarkably reduced by Tau in the case of the suppository containing 10-mg C12. The reason for the different effect of Tau remains to be clarified.
Then, we examined the absorption-improving effect of the suppositories containing C12 only or C12 with Tau, which was compared with the suppositories containing C10 (C10 suppositories). Figure 3 shows the serum concentrationtime profiles of rebamipide after rectal administration of the seven typical suppositories containing 5 mg rebamipide, and Table 5 shows pharmacokinetic parameters for all the suppositories examined. Serum concentration-time profiles of rebamipide after intravenous administration at a dose of 1.15 mg/kg was described by the following equation: Cpϭ34.6·e
ϩ2.5·e Ϫ2.1t mg/ml and AUC from 0 to infinite was calculated as 3.69Ϯ0.62 mg·h/ml (nϭ4). The suppositories containing 15-and 25-mg C10 (suppositories a, b) enhanced the absorption of rebamipide about 25 and 40 times larger in BA than the control, respectively. On the other hand, the suppositories e and f, containing the smaller amount of C12 than C10, enhanced the absorption of rebamipide about 27 and 56 times larger in BA than the control, respectively. These results clearly show that C12 improved the absorption of rebamipide more than C10. Although we have already reported that C12 was better than C10 in terms of absorptionimproving ability, 24, 25) the same effect was recognized in the present study using rabbits. The suppositories containing 10-mg C12 with 15-, 30-and 60-mg Tau (suppositories g, h, i), and 20-mg C12 with 30-mg Tau (suppository j) enhanced the absorption of rebamipide about 22, 16, 8 and 51 times larger in BA than the control. AUC, C max and BA of rebamipide for suppository j were significantly greater than those for suppository b, containing 25-mg C10 (pϽ0.05), indicating that suppository j is better than commercial products in terms of absorption enhancement. As rebamipide is a poorly watersoluble and poorly absorbable drug, [14] [15] [16] [17] [18] [19] [20] the improvement of both dissolution and membrane permeability should be needed to enhance the absorption of rebamipide. The enhancement of membrane permeability by C12 was already The compositions of suppositories examined are summarized in Table 3 . Results are expressed as the mean with the bar showing S.E. value of three to five experiments. Keys: ϫ, Control suppository; ᭺, suppository f (20 mg C12); ᭹, suppository j (20 mg C12ϩ30 mg Tau); ᭝, suppository a (15 mg C10); ᭡, suppository b (25 mg C10); ٗ, suppository e (10 mg C12); , suppository h (10 mg C12ϩ30 mg Tau). Table 4 evidenced, 26, 27) which might be attributed to the opening of tight junction and the enhancement of membrane fluidity. 26) Although we previously reported that the addition of Tau attenuated the enhancing effect of C12, 25, 30) Tau hardly decreased the absorption improving effect of C12 in the case of the suppositories containing 20-mg C12, when compared with the suppositories containing 10-mg C12 (Fig. 3) . The reason for it remains to be clarified, but Fig. 2 and Table 4 show that the dissolution rate of rebamipide from the suppository containing 20-mg C12 was not attenuated by Tau so much, but the rate was decreased by Tau in the case of the suppository containing 10-mg C12, which might be one of possible reasons.
To estimate the cytoprotective action by the suppositories containing C12 and Tau (C12-Tau suppositories), the histopathological examination was performed (Fig. 4 , Table  5 ). Figure 4 shows the typical picture of the rectal mucosa 6 h after the rectal administration of control suppository (A), suppository j, containing both 20-mg C12 and 30-mg Tau (B) or suppository b, containing 25-mg C10 only (C). Table  5 shows the results of histopathological scores and classification of irritation for each suppository. The suppositories containing 2-to 20-mg C12 were evaluated as B to C-D in rank by following the overall evaluation criteria of irritation ( Table   5 ), showing that the mucosal irritation by C12 also became severer dose-dependently. The suppositories containing 10-mg C12 with 15-, 30-and 60-mg Tau were evaluated as C, B and B in rank, respectively, indicating that 30-and 60-mg Tau exerted the cytoprotective action. In the case of suppositories containing 20-mg C12, the rank was shifted from C-D to C by the addition of 30-mg Tau. These results confirmed that Tau could attenuate the irritation caused by C12 in rabbit rectal mucosa as well. On the other hand, the suppository containing 15-or 25-mg C10, the same amounts of C10 as the commercially available suppositories have, was evaluated as C or C-D in rank, respectively (Table 5 ). Histopathological examination revealed that suppository b, containing 25-mg C10, caused erosion, flattening of epithelial cells and inflammatory cell infiltration such as pseudoeosinophil of lamina propria in the rabbit rectum (Fig. 4  C) . However, these damages were decreased by the combinatorial use of 20-mg C12 with 30-mg Tau (Fig. 4 B, Table 5 ).
Taken all together, the suppository preparation j, containing 20-mg C12 and 30-mg Tau, could be better than suppository b, containing 25-mg C10, in both absorption enhancement and safety. Compared with suppository a, containing 15-mg C10, the suppository preparation h, containing 10-mg C12 and 30-mg Tau, is also a promising formulation, considering the balance between efficacy and safety. Although the absorption-enhancing ability of suppository h is lower than that of suppository a, it is still around 13 times larger than control suppository and the safety is much higher than that of suppository a (Table 5) . These results clearly show that the combinatorial use of C12 with Tau enables us to provide absorption-improving suppository formulations, which are safer and more effective than the commercially available products containing C10, would be available for practical use in human.
CONCLUSION
In the present study, we focused on the scaling up study of animal and formulation size in order to make it possible practically to use C12-Tau suppositories in human. Although we've already reported that the suppository containing 2-mg C12 and 6-mg Tau, of which size is 10ϫ3 mm i.d., was potent in both safety and efficacy, 30) it was difficult to estimate if this formulation was good enough in human, too. We were successful in showing that C12-Tau suppositories were promising by applying larger suppositories (15ϫ6 mm i.d.) with different compositions to rabbits. Furthermore, the comparison with C10 suppositories in both absorption-enhancing ability and safety also evidenced that the combinatorial use of C12 with Tau could provide the practical suppositories safer and more effective than the commercially available products containing C10. 
